Spinocerebellar Ataxia: miRNAs

microRNAs (miRNAs) are key regulatory RNAs that control gene expression in various biological processes and human diseases such as Spinocerebellar Ataxia. Here are the latest discoveries pertaining to miRNAs and this disease.

December 9, 2021

MiRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.

Nucleic Acid Therapeutics
Rui Jorge NobreLodewijk J Toonen
October 28, 2021
Open Access

Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system.

Brain Communications
Marina Sogorb-GonzalezAstrid Vallès
October 20, 2021

Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain.

Nature Medicine
Megan S KeiserBeverly L Davidson
June 17, 2021

Making sense of mRNA landscapes: Translation control in neurodevelopment.

Wiley Interdisciplinary Reviews. RNA
Yongkyu ParkMladen-Roko Rasin
March 22, 2021
Open Access

Staufen1 in Human Neurodegeneration.

Annals of Neurology
Sharan PaulStefan M Pulst
December 20, 2020
Open Access

Competing Endogenous RNA Networks as Biomarkers in Neurodegenerative Diseases.

International Journal of Molecular Sciences
Leticia Moreno-GarcíaRosario Osta
September 3, 2020
Open Access

UTteR control through miRs: fine-tuning ATXN1 levels to prevent ataxia.

Genes & Development
Mingyi Xie, Maurice S Swanson
August 30, 2020
Open Access

PKCγ-Mediated Phosphorylation of CRMP2 Regulates Dendritic Outgrowth in Cerebellar Purkinje Cells.

Molecular Neurobiology
Sabine C WinklerJosef P Kapfhammer
August 9, 2020
Open Access

miR760 regulates ATXN1 levels via interaction with its 5' untranslated region.

Genes & Development
Larissa NitschkeHuda Y Zoghbi
July 30, 2020

Ataxic phenotype and neurodegeneration are triggered by the impairment of chaperone-mediated autophagy in cerebellar neurons.

Neuropathology and Applied Neurobiology
Masahiro SatoTakahiro Seki
July 9, 2020
Open Access

Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain

Molecular Therapy. Methods & Clinical Development
Josse A DeplaMelvin M Evers
December 13, 2019
Open Access

Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease

Molecular Therapy. Methods & Clinical Development
Raygene MartierMelvin M Evers
July 6, 2019
Open Access

The Emerging Role of microRNAs in Polyglutamine Diseases

Frontiers in Molecular Neuroscience
Xiaoyu Dong, Shuyan Cong
June 13, 2019
Open Access

State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change

Genetics and Molecular Biology
Gabriel Vasata FurtadoLaura Bannach Jardim
March 14, 2019
Open Access

Modeling Neurodegenerative Spinocerebellar Ataxia Type 13 in Zebrafish Using a Purkinje Neuron Specific Tunable Coexpression System

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
Kazuhiko NamikawaReinhard W Köster
February 6, 2019

Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7

Molecular Neurobiology
Verónica M Borgonio-CuadraJonathan J Magaña
January 22, 2019
Open Access

The Role of MicroRNAs in Spinocerebellar Ataxia Type 3

Journal of Molecular Biology
Sybille Krauß, Bernd O Evert

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved